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Abstract
Vascular endothelial growth factor (VEGF165) is a potent angiogenic mitogen commonly overexpressed in cancerous cells. It
contains two main binding domains, the receptor-binding domain (RBD) and the heparin-binding domain (HBD). This study
attempted to identify the specific sequences of the VEa5 DNA aptamer that exhibit high binding affinity towards the
VEGF165 protein by truncating the original VEa5 aptamer into different segments. Using surface plasmon resonance (SPR)
spectroscopy for binding affinity analysis, one of the truncated aptamers showed a .200-fold increase in the binding
affinity for HBD. This truncated aptamer also exhibited high specificity to HBD with negligible binding affinity for VEGF121,
an isoform of VEGF lacking HBD. Exposing colorectal cancer cells to the truncated aptamer sequence further confirmed the
binding affinity and specificity of the aptamer to the target VEGF165 protein. Hence, our approach of aptamer truncation can
potentially be useful in identifying high affinity aptamer sequences for the biological molecules and targeting them as
antagonist for cancer cell detection.
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Introduction
Short single stranded nucleic acids referred to as aptamers are
widely being explored as molecules of high affinity and specificity
for binding a diverse array of target molecules ranging from high
molecular weight proteins to small ions and nucleotides [1–3].
Aptamers contain functional moieties that fold into different
secondary conformations, such as hairpin stem and loops, G-
quadruplexes, bulges and pseudoknots, and they exhibit substan-
tial impact on the conformational stability and target binding
affinity of the aptamer. The non-immunogenic property of
aptamer provides additional advantage over the prevalent
antibodies and makes them a promising candidate for therapeutic
and diagnostic application [4]. ‘‘Macugen’’ is the first FDA-
approved aptamer-based therapeutic for treating the wet-form of
age-related macular degeneration. The successful approval of this
27-mer RNA aptamer as therapeutic drug in 2004 has
demonstrated the potential of aptamers as future therapeutics
[5]. Currently, 8 aptamers are in various phases of clinical trials for
treating different diseases [6–13]. These include NOX-E36 L-
RNA aptamer against CCL2 ligand in Type 2 diabetes, G-
quadruplex forming AS1411 DNA aptamer against nucleolin
in acute myeloid leukemia, and phosphorothioate-modified
ARC1779 DNA aptamer against von Willebrand factor (vWF)
in carotid artery disease [7,8,10].
Aptamers are commonly screened and obtained by in vitro
selection technique, also termed as systematic evolution of ligands
by exponential enrichment (SELEX). SELEX starts with a
random pool of oligonucleotide library incubated with the target
molecule and involves continuous rounds of affinity and
amplification steps to screen for the high affinity sequences
[14,15]. Different selection process has been used for isolation of
high binding affinity aptamers in SELEX, such as nitrocellulose
membrane filtration, surface plasmon resonance (SPR), capillary
electrophoresis and bead-based methods [15–18]. Binding affinity
and specificity are the crucial criteria for the therapeutic use of
aptamers. Generally, not all nucleotide domains of the post-
screened aptamer play an important role in target binding. The
non-binding domain may actually interfere with the interaction
between the aptamer and target protein by formation of complex
secondary structures, and eventually prevents the binding domain
to fold into the desired conformation for binding to the target [4].
This may result in reduction or complete loss of the binding
affinity as well as higher synthesis cost. Therefore, identifying the
high binding affinity domains in the post-screened aptamer is a key
step to perform for producing potent aptamers with higher
affinity/specificity for various biomedical applications.
Different strategies have been adopted to enhance the aptamer
binding affinity for its target and to make them suitable for
different biological applications. One of the commonly used
strategies includes chemical modification of the aptamer structure
at 59-o r3 9-terminus, nucleobase, sugar, and phosphate backbone.
The modifications include (i) the addition of functional groups,
such as amino (-NH2), fluoro (-F), O-methyl (-OCH3), locked
nucleic acids (LNAs) or phosphorothioate linkages (PS-linkages) to
make aptamers nuclease resistant, and (ii) conjugation with high
molecular weight polyethylene glycol (PEG) to enhance in vivo
circulating half-life [5,19–26]. Apart from improving the stability
of the aptamer, these modifications can improve the affinity of the
aptamer in the cellular environment. Additionally, software
algorithms have been used to deduce the binding domains by
comparing different sequences as well as to predict the secondary
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31196structure [27,28]. Strategies such as partial fragmentation,
enzymatic footprinting, and recently microarray based binding
sequence determination have also been employed for probing the
high affinity binding sequences [13,29,30].
Vascular endothelial growth factor (VEGF) is a mitogenic
protein secreted by both endothelial and tumor cells and induces
physiological and pathological angiogenesis inside the body.
Through alternate exon splicing of single human VEGF gene,
several isoforms of this growth factor, including VEGF165,
VEGF121, VEGF189 and VEGF206, are generated [31]. Of these,
VEGF165 and VEGF121 are the predominant isoforms. VEGF165,
which contains both heparin-binding domain (HBD) and receptor-
binding domain (RBD), has been shown to be a more potent
mitogen in inducing angiogenesis compared with VEGF121, which
contains only RBD [32–34].
A previous work by Ikebukuro and co-workers has identified a
66mer DNA aptamer (VEa5) that binds to HBD of VEGF165
protein with Kd value of 130 nM [35]. Since increasing the
binding affinity of this aptamer is important for further therapeutic
development, they later adopted the dimerization method to
reduce the Kd of VEa5 aptamer to 6 nM, which is 20 times better
than the original monomeric VEa5 [36]. In the present study, we
adopted a different strategy to improve the binding affinity of the
VEa5 aptamer. We attempted to identify the high affinity binding
sequences within the 66mer VEa5 by truncating its stem-loop
regions and investigated the impact on the binding affinity against
HBD of VEGF165 protein using surface plasmon resonance (SPR)
spectroscopy. Our results demonstrated that the truncation of the
stem-loop regions can locate the key binding domain in the
aptamer and the truncated sequence exhibits substantially higher
binding affinity compared with the entire VEa5 aptamer. In vitro
binding study with colorectal cancer cells overexpressed with
VEGF protein further confirmed the high binding affinity of the
truncated aptamer.
Materials and Methods
Materials
The HPLC purified oligonucleotides (both unlabeled and
fluorescent-labeled) were purchased from Sigma-Aldrich. The
recombinant human carrier free VEGF165 (molecular weight of
38 kDa, pI=8.25) and VEGF121 (molecular weight of 28 kDa,
pI=6.4) proteins were purchased from R & D systems. CM5
sensor chips were purchased from GE Healthcare for protein
immobilization. 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide
hydrochloride (EDC), N-hydroxysuccinimide (NHS), and ethanol-
amine-HCl were purchased from Sigma-Aldrich. Sodium acetate
(anhydrous) was purchased from Fluka. Human colorectal
adenocarcinoma HT-29 cell line was a gift from Dr. Partha Roy’s
lab. Normal human fetal lung fibroblast MRC-5 cells were
obtained from ATCC. Dulbecco’s modified eagle’s media
(DMEM) media, RPMI-1640 and fetal bovine serum (FBS) was
purchased from Caisson laboratories. Trypsin-EDTA and 1%
penicillin/streptomycin mixture were purchased from PAN
biotech. Phosphate buffer saline (PBS) buffer was purchased from
1
st Base. Tween-20 was purchased from USB Corporation.
Binding affinity of truncated aptamers via surface
plasmon resonance spectroscopy
To elucidate the role of stem-loop regions of the VEa5 aptamer
in VEGF binding, the original sequence of the VEa5 was
truncated. The corresponding binding affinity of truncated
aptamers was investigated using surface plasmon resonance
(SPR) spectroscopy, where VEGF165 and VEGF121 acted as
ligands and were directly immobilized on the sensor chip. Briefly,
the carboxylic group on the sensor chip was activated by standard
amine coupling procedure using freshly prepared EDC/NHS.
VEGF165 or VEGF121 (25 mg/ml) in acetate buffer (pH 6.0) was
then injected into the sensor chip at flow rate 8 ml/min to reach
,200RU immobilization level. The deactivation was done by
ethanolamine-HCl to block unreacted carboxyl groups. The
binding analysis was carried out with truncated aptamers at
different concentrations (0.2 to 100 nM) using a BIAcore 2000
instrument (GE Healthcare). The running condition was set at
30 ml/min flow rate, 25uC, 3 min association time and 5 min
dissociation time. PBS and 0.005% tween-20 solution mixture was
used as the running buffer, and 50 mM NaOH as the regeneration
buffer. All the buffers were filtered and degassed prior to each
experiment. Blank surfaces were used for background subtraction.
Upon injection of the truncated aptamers, sensorgrams recording
the association/dissociation behavior of the VEGF-aptamer
complex were collected. By varying the truncated aptamer
concentration, a series of sensorgrams (Figure 1) were obtained
and subsequently analyzed using the 1:1 Langmuir model
provided in the BIAevaluation software (version 4.1) to calculate
the equilibrium dissociation constant Kd. All SPR measurements
were performed in triplicates.
Cellular binding of truncated aptamer via flow cytometry
analysis
The HT-29 colorectal cancer and MRC-5 human fetal lung
fibroblast cells were plated at a seeding density of 10
5 cells/ml in
DMEM and RPMI-1640 media and were allowed to attach for
48 hours in humidified incubator containing 5% CO2,1 %O 2 and
94% N2 (hypoxia) at 37uC. The hypoxia condition was maintained
by culturing the cells in a sealed hypoxia chamber (Billups-
Rothenberg). The cells were trypsinized for very short time and
incubated with 59-PE-texas red labeled truncated aptamer of
different concentrations for 2 hours at 37uC in culture medium.
The cells were then centrifuged for 5 min at 1500 rpm and re-
suspended in PBS buffer for flow cytometry analysis immediately.
Analysis was performed on a Beckman-Coulter CyAn ADP flow
cytometer using 488 nm excitation and 613/20 nm emission filter.
20,000 events were collected for each sample. All the experiments
for binding assay were repeated at least 3 times. Relative
fluorescence was determined using SUMMIT V 4.3.02 software.
For calculation of equilibrium dissociation (Kd), the fluorescence
intensity signal was plotted against fluorescently labeled aptamer
concentration by fitting in equation Y=Bmax X/(Kd+X) using
SigmaPlot software. Sequence specificity of the SL2-B aptamer was
determined using a scrambled sequence. The Kd value of the SL2-
B aptamer was calculated by subtracting the fluorescence intensity
signal from the scrambled sequence.
Competitive aptamer binding assay was performed to determine
the effect of unlabeled SL2-B aptamer on the binding capability of
59-PE-texas red labeled truncated aptamer. HT-29 colorectal
cancer cells were incubated with 20-fold excess concentration of
unlabeled aptamer as competitor (10 nM) simultaneously with 59-
PE-texas red labeled aptamer (0.5 nM). All other experimental
conditions and procedures were same as described for the flow
cytometry analysis.
Fluorescence microscopy imaging
The HT-29 cells and MRC-5 cells were seeded in 24-well plate
in DMEM and RPMI-1640 media respectively. Cells were plated
at a seeding density of 10
5cells/ml in their individual media
supplemented with FBS and penicillin/streptomycin mixture in
the same hypoxic conditions as mentioned above. Subsequently,
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aptamer at 37uC for 2 hours and washed with PBS (pH=7.4)
three times to remove unbound aptamer. Sequence specificity of
the truncated aptamer was determined using a scrambled
sequence as control. Images of aptamer binding to cells were
acquired using a Leica DMIL fluorescence microscope.
Statistical analysis
Results from at least 3 independent experiments in flow
cytometry experiment were analyzed using Student’s t-test. p-
value,0.05 was considered significant. Data are expressed as
mean 6 S.D.
Results and Discussion
Binding analysis of aptamer-VEGF complex by surface
plasmon resonance (SPR)
The induction of the aptamer folding was done using
predictions by the mfold software [37]. As shown in Figure 2,
VEa5 displays complex hairpin stem-loop secondary structure
with three stem-loop regions and several unpaired terminal
nucleotides. Based on the SPR measurement, the original VEa5
aptamer exhibited a binding constant of Kd=120 nM to the
surface immobilized VEGF165 (Table 1). This value is very close to
the Kd value of the VEa5 aptamer binding to the heparin-binding
domain (HBD) of VEGF165 reported in the literature
(Kd=130 nM) [35].
To better understand the significance of stem-loop (SL) regions
towards binding affinity, we conducted a few truncations on the
SL regions. By truncating SL3 at the 39 end together with 39-
termini hanging nucleotides and the nucleotides between SL2 and
SL3, we obtained SL12 (Figure 3A and Table 1) and it exhibited a
Kd value of 5 nM, a striking 24-fold increase in the binding affinity
compared with the original VEa5 aptamer. Further truncation of
SL2 to yield SL1 (Figure 3B and Table 1), however, resulted in
complete loss of binding activity towards VEGF165. These two
modifications pointed to the indispensable role of SL2 in the
binding process. The increase in the binding affinity could be due
to the deletion of non-binding nucleotides that hampers the
Figure 1. Typical SPR sensorgrams demonstrating interaction of aptamer with immobilized VEGF165 protein at different
concentrations (bottom to top, 0.2 to 100 nM). Point A to B corresponds to the association phase and point B to C corresponds to the
dissociation phase in all the sensorgrams. Shown here is the SL2-B aptamer (Kd=0.5060.32 nM).
doi:10.1371/journal.pone.0031196.g001
Figure 2. Schematic representation of the secondary structure
of original VEa5 aptamer as predicted by the mfold program.
Nucleotide 4–20 forms the stem-loop 1 (SL1) region, nucleotide 22–38
forms the stem-loop 2 (SL2) region, and nucleotide 43–50 forms stem-
loop 3 (SL3) region. Nucleotide 28–33 forms internal loop 1 (IL1), and
nucleotide 24–27+34–36 together forms internal loop 2 (IL2) within SL2
region.
doi:10.1371/journal.pone.0031196.g002
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desired secondary conformation in the truncated aptamer required
for binding to the HBD of VEGF165 protein [28].
We next truncated SL1 and left with only the SL2 sequence for
VEGF165 binding analysis, and surprisingly we obtained lower
binding affinity. With Kd value of 49 nM (Figure 3C and Table 1),
the binding affinity of the SL2 sequence was approximately 10
times higher than the Kd of SL12. This prompted us to further
investigate the role of the additional sequence next to the 39 and 59
ends of the SL2 region. By adding a single nucleotide at both 59
and 39-ends of the SL2 aptamer (SL2-A, Figure 3D), we were able
to lower the Kd value by almost 5-fold (Kd=10 nM, Table 1)
compared to the SL2 aptamer. Further addition of nucleotides to
39-end did not yield any improvement in the binding affinity.
However, adding another 7 nucleotides at 59-end of the SL2
aptamer (SL2-B, Figure 3E) showed further enhancement in the
binding affinity (Kd=0.5 nM, Table 1), and this represented a 90-
fold increase compared with the SL2 aptamer, and more than 200-
fold increase compared with the original VEa5 aptamer and 10-
fold increase compared with the dimerized VEa5 aptamer [36]. A
possible explanation is that the addition of nucleotides to the 59-
end provides more conformational stability to the aptamer which
Table 1. Different aptamer sequences along with their equilibrium dissociation constant (Kd) values determined using surface
plasmon resonance (SPR) spectroscopy.
Sequences of original and various truncated aptamers (59------ 39)* Kd
VEa5 ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA 12061.8 nM
SL12 ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA 560.45 nM
SL1 ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA No Binding
SL2 ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA 4962.4 nM
SL2-A ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA 1061.1 nM
SL2-B ATACCAGTCTATTCAATTGGGCCCGTCCGTATGGTGGGTGTGCTGGCCAGATAGTATGTGCAATCA 0.560.32 nM
*The underlined and bold section indicates the aptamer sequence and the non-bold grey section indicates the truncated sequence. In aptamer sequence terminology,
the subscript number indicates the presence of the particular stem-loop region.
doi:10.1371/journal.pone.0031196.t001
Figure 3. Schematic representation of the secondary structures of various truncated aptamers as predicted by the mfold program.
(A) SL12 indicates the presence of SL1 and SL2 regions together, (B) SL1 indicates the presence of SL1 region only and (C) SL2 indicates the presence of
SL2 region only. (D) SL2-A and (E) SL2-B correspond to secondary structures formed after addition of nucleotides to SL2 region.
doi:10.1371/journal.pone.0031196.g003
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spectroscopy. Point A to B corresponds to the association phase and point B to C corresponds to the dissociation phase in the sensorgrams. Shown
here is SL2-B aptamer binding with VEGF165 protein (Kd=0.5060.32 nM) and VEGF121 protein (Kd=10.261.89 mM).
doi:10.1371/journal.pone.0031196.g004
Figure 5. Representative flow cytometry profiles and quantitative analysis of flow cytometry results in (A) HT-29 cells and (B) MRC-
5 cells after SL2-B aptamer at different concentrations (red – 0 nM (negative control), green – 0.5 nM, pink – 10 nM, blue – 100 nM),
**Significant difference compared with the negative control (p-value,0.001), n.s. – not significant.
doi:10.1371/journal.pone.0031196.g005
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[38]. We also attempted to truncate the internal loops of SL2 (IL1
and IL2, Figure 2) but the removal of either loops reduced the
binding affinity. Therefore, SL2-B is thought to be the minimal
sequence required in VEa5 aptamer to provide high binding
affinity to HBD of VEGF165.
To address the selectivity of the truncated SL2-B aptamer to
VEGF165 binding, VEGF121 was selected for the binding
comparison. VEGF121 is another spliced form of VEGF mRNA
that constitutes only the receptor-binding domain (RBD) but is
devoid of HBD. HBD assists in the binding of VEGF protein to
the heparin sulfate (HS) and heparin sulfate proteoglycans
(HSPGs) present on the extracellular matrix of the cell membrane
[32]. This enhances the interaction of VEGF with its receptors
(VEGFR-1/Flt-1 and VEGFR-2/KDR) and the specific co-
receptor neuropilins, triggering the cellular angiogenic response
in malignant cells [34].
Compared with VEGF165, the binding of VEGF121 to the
membrane receptors is not strong, making it not potent to generate
intense angiogenic signal. Using SL2-B for binding analysis with
VEGF121 under same buffer condition (Figure 4), substantial
reduction in the response signal and minimal binding
(Kd=10.2 mM) was observed compared to VEGF165. This
confirms the binding selectivity of the truncated SL2-B aptamer
on HBD of the VEGF165 protein.
In vitro cellular binding analysis of SL2-B aptamer-VEGF
complex
Compared to techniques such as nitrocellulose membrane
filtration or capillary electrophoresis, cell-based technique, such as
flow cytometry, isolates aptamer sequences that have the ability to
bind to their target with high affinity and specificity in a more
physiologically relevant environment [39,40]. Thus, it has been
considered as a more direct strategy for studying the binding of
aptamers to their targets on cellular surface.
To validate the increase in the binding affinity of the truncated
SL2-B aptamer and to determine its target specificity at cellular
level, we exposed the fluorescent-labeled SL2-B sequence directly
on the HT-29 colorectal cancer cells and normal MRC-5
fibroblast cells (control) under 1% O2 hypoxia condition by flow
cytometry analysis. As shown in Figure 5A, a significant peak shift
(increase in the fluorescent signal) was observed for SL2-B aptamer
at different concentrations, compared to control sample (only cells)
in response to hypoxia conditions in HT-29 cells (p-value,0.001).
The percentage of fluorescent-labeled cells increased with the
increase in the concentration of the SL2-B aptamer, indicating the
binding of the SL2-B aptamer to the cell surface. In contrast, when
using normal MRC-5 fibroblast cells, no enhancement in the
fluorescent signal was observed after treatment with different SL2-
B aptamer concentrations (Figure 5B, not significant (n.s.)
compared to negative control). Since the VEGF protein is
overexpressed in HT-29 cells but not the normal MRC-5 cells,
the result showed that SL2-B can specifically form aptamer-VEGF
complex on the HT-29 cell membrane. The Kd value of the SL2-B
towards VEGF was further evaluated using flow cytometry data
(Figure 6). The Kd value for the SL2-B aptamer to the cell surface
was found to be 1.0 nM, which is close to the Kd value determined
by SPR technique (Figure 6). Repeating the same experiment at
Figure 6. Binding curve of SL2-B aptamer with HT-29 cells. Cells
were incubated with different SL2-B aptamer concentrations ranging
from 0 to 100 nM. The fluorescence intensity originating from the
scrambled sequence at each concentration was subtracted from the
fluorescence intensity of corresponding SL2-B aptamer. The actual
fluorescence intensity was fitted into SigmaPlot software to determine
the Kd.
doi:10.1371/journal.pone.0031196.g006
Figure 7. Flow cytometry histogram showing binding competition between the labeled and unlabeled SL2-B aptamer in HT-29 cells
and quantitative analysis of flow cytometry result. Red – 0 nM (negative control), green – aptamer binding without excess of unlabeled SL2-B
aptamer (0.5 nM); pink – aptamer binding in excess of unlabeled SL2-B aptamer (unlabeled aptamer – 10 nM, labeled aptamer – 0.5 nM). *Significant
difference from the negative control sample at p-value,0.05; **Significant difference from the negative control sample at p-value,0.001.
doi:10.1371/journal.pone.0031196.g007
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binding of SL2-B aptamer to the cells. The result is in agreement
with the fact that the hypoxia condition enhances production of
VEGF protein in HT-29 cells [41–43].
Hypoxia is one of the crucial physiological factors that exert
profound impact on the metabolism, invasion and tumor
progression, thereby affecting many oncogenic pathways. Inade-
quate level of cellular oxygen leads to aggressive phenotypic
changes in the tumor cells, and is primarily responsible for their
resistance against the therapies and poor prognosis [44]. Exposure
to hypoxia milieu upregulates the expression of master regulator
Hypoxia-Inducible Factor 1 gene (HIF-1 gene) in the solid tumors,
which switch on the transcription of several downstream genes, in
particular, VEGF [45]. The expression of VEGF protein and its
two tyrosine kinase receptors – VEGFR-1/Flt-1 and VEGFR-2/
KDR is induced by the transcription and stabilization of VEGF
mRNA in response to hypoxia, resulting in increase rate of
vascularization in tumor [46–48].
The binding ability of SL2-B aptamer for VEGF protein in HT-
29 cells was evaluated by competing 59-PE-texas red labeled SL2-B
sequence against the unlabeled SL2-B sequence. As shown in
Figure 7, the presence of 20-fold excess of unlabeled aptamer
significantly decreased the fluorescent signal from the PE-texas red
labeled aptamer (p-value,0.05). This result suggests that both the
labeled and unlabeled SL2-B aptamer binds to the same target, the
VEGF protein on HT-29 cell membrane.
In vitro fluorescence imaging of SL2-B aptamer-VEGF
complex
The targeting ability and specificity of the high affinity SL2-B
aptamer was further investigated and imaged using live colorectal
cancer HT-29 cells and normal MRC-5 fibroblast cells (control) at
Figure 8. Binding of PE-texas red-labeled aptamers (SL2-B and scrambled sequence) to HT-29 cells and normal MRC-5 fibroblast
cells under hypoxia condition. (A) & (C) Bright field images of HT-29 cells after exposing to the SL2-B and scrambled sequence respectively. (B) &
(D) Corresponding fluorescence microscopy images of the (A) & (C) bright field images. (E) & (F) Bright field and fluorescence microscopy images of
MRC-5 cells after exposing to the SL2-B sequence.
doi:10.1371/journal.pone.0031196.g008
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the fluorescent images, we observed red fluorescence on HT-29
cells after exposing to PE-texas red labeled SL2-B aptamer
(Figure 8A & B), but no detectable fluorescence was observed
with PE-texas red labeled scrambled sequence (Figure 8C & D).
This confirms the specific binding of SL2-B aptamer to VEGF165
protein in cancer cells. For MRC-5 fibroblasts, minimal
fluorescence was also observed after exposing to the same SL2-B
aptamer (Figure 8E & F). This further demonstrates the specificity
and targeting ability of the SL2-B aptamer to cancer cells.
Conclusions
To summarize, this work attempted to identify in the key
binding aptamer sequences by truncating based on the stem-loop
structure of the original VEa5 aptamer. From the results, we can
conclude that the SL2 sequence is important for the binding to
HBD of the VEGF165 protein, and the SL2-B aptamer binds HBD
of VEGF165 protein strongly and selectively. This newly obtained
SL2-B aptamer sequence can potentially be useful in oligomer-
based cancer therapeutic and diagnostic applications, though
further studies are required for better understanding of the SL2-B
aptamer sequence and to elucidate its binding mechanism with
HBD of VEGF165 protein. Furthermore, the current stem-loop
modification approaches can be useful in identifying target
domains, getting rid of excessive unnecessary nucleotides, and
eventually lowering the cost of aptamer synthesis.
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